Obesity, Abdominal Obesity, and Insulin Resistance

Clinical Cornerstone

Volumn 9, Issue 1, 2008, Pages 23-31

  Westphal, Sydney A ^a  

^a MARICOPA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; CYTOKINE; FATTY ACID; INSULIN; METFORMIN; PLACEBO; RIMONABANT;

ABDOMINAL OBESITY; ADIPOSE TISSUE; AGE; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG MECHANISM; DYSLIPIDEMIA; FITNESS; GLUCOSE INTOLERANCE; HIGH RISK PATIENT; HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOARTHRITIS; PHYSICAL ACTIVITY; RISK ASSESSMENT; SIDE EFFECT; SLEEP APNEA SYNDROME; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOKINES; ADIPOSE TISSUE; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; HUMANS; INSULIN RESISTANCE; MOTOR ACTIVITY; OBESITY; RISK; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 56849101309     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(08)60025-3     Document Type: Article

References (47)

1. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
2. Stein C.J., and Colditz G.A. The epidemic of obesity. J Clin Endocrinol Metab 89 (2004) 2522-2525
3. Nathan D.M., and Cagliero E. Diabetes mellitus. In: Felig P., and Frohman L.A. (Eds). Endocrinology and Metabolism. 4th ed. (2001), McGraw Hill Publishing Inc, New York, NY 827-926
4. Hutley L., and Prins J.B. Fat as an endocrine organ: Relationship to the metabolic syndrome. Am J Med Sci 330 (2005) 280-289
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
6. Rosenbaum M., Leibel R.L., and Hirsch J. Obesity. N Engl J Med 337 (1997) 396-407
7. De Lorenzo A., Deurenberg P., Pietrantuono M., et al. How fat is obese?. Acta Diabetol 40 Suppl 1 (2003) S254-S257
8. US Preventive Services Task Force. Screening for obesity in adults: Recommendations and rationale. Ann Intern Med 139 (2003) 930-932
9. Colditz G.A., Willett W.C., Rotnitzky A., and Manson J.E. Weight gain as a risk factor for clinical diabetes in women. Ann Intern Med 122 (1995) 481-486
10. Chan J.M., Rimm E.B., Colditz G.A., et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17 (1994) 961-969
11. Peeters A., Barendregt J.J., Willekens F., et al., for the NEDCOM, the Netherlands Epidemiology and Demography Compression of Morbidity Research Group. Obesity in adulthood and its consequences for life expectancy: A life-table analysis. Ann Intern Med 138 (2003) 24-32
12. Calle E.E., Thun M.J., Petrelli J.M., et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 341 (1999) 1097-1105
13. Adams K.F., Schatzkin A., Harris T.B., et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 355 (2006) 763-778
14. Jee S.H., Sull J.W., Park J., et al. Body-mass index and mortality in Korean men and women. N Engl J Med 355 (2006) 779-787
15. Ruderman N., Chisholm D., Pi-Sunyer X., and Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 47 (1998) 699-713
16. Dvorak R.V., DeNino W.F., Ades P.A., and Poehlman E.T. Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes 48 (1999) 2210-2214
17. Wei M., Kampert J.B., Barlow C.E., et al. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. JAMA 282 (1999) 1547-1553
18. Sui X., LaMonte M.J., Laditka J.N., et al. Cardiorespiratory fitness and adiposity as mortality predictors in older adults. JAMA 298 (2007) 2507-2516
19. Stevens J., Cai J., Pamuk E.R., et al. The effect of age on the association between body-mass index and mortality. N Engl J Med 338 (1998) 1-7
20. Pi-Sunyer F.X. The epidemiology of central fat distribution in relation to disease. Nutr Rev 62 (2004) S120-S126
21. Després J.P., Lemieux I., and Prud'homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients. BMJ 322 (2001) 716-720
22. Kissebah A.H., Freedman D.S., and Peiris A.N. Health risks of obesity. Med Clin North Am 73 (1989) 111-138
23. Pouliot M.C., Després J.P., Nadeau A., et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 41 (1992) 826-834
24. Tankó L.B., Bagger Y.Z., Alexandersen P., et al. Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation 107 (2003) 1626-1631
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
26. Carey D.G., Jenkins A.B., Campbell L.V., et al. Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 45 (1996) 633-638
27. O'Shaughnessy I.M., Myers T.J., Stepniakowski K., et al. Glucose metabolism in abdominally obese hypertensive and normotensive subjects. Hypertension 26 (1995) 186-192
28. Kelley D.E., Thaete F.L., Troost F., et al. Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol EnJocrinol Metab 278 (2000) E941-E948
29. Cnop M., Landchild M.J., Vidal J., et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: Distinct metabolic effects of two fat compartments. Diabetes 51 (2002) 1005-1015
30. Rönnemaa T., Koskenvuo M., Marniemi J., et al. Glucose metabolism in identical twins discordant for obesity. The critical role of visceral fat. J Clin Endocrinol Metab 82 (1997) 383-387
31. Pouliot M.C., Després J.P., Lemieux S., et al. Waist circumference and abdominal sagittal diameter: Best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 73 (1994) 460-468
32. Kahn B.B., and Flier J.S. Obesity and insulin resistance. J Clin Invest 106 (2000) 473-481
33. Aldhahi W., and Hamdy O. Adipokines, inflammation, and the cndothelium in diabetes. Curr Diab Rep 3 (2003) 293-298
34. Bastard J.P., Maachi M., Lagathu C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17 (2006) 4-12
35. Badman M.K., and Flier J.S. The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 132 (2007) 2103-2115
36. Kahn S.E., Hull R.L., and Utzschneider K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444 (2006) 840-846
37. Laclaustra M., Corella D., and Ordovas J.M. Metabolic syndrome pathophysiology: The role of adipose tissue. Nutr Metab Cardiovasc Dis 17 (2007) 125-139
38. Qatanani M., and Lazar M.A. Mechanisms of obesity-associated insulin resistance: Many choices on the menu. Genes Dev 21 (2007) 1443-1455
39. Stolar M. Metabolic syndrome: Controversial but useful. Cleve Clin J Med 74 (2007) 199-202 205-208.
40. Kershaw E.E., and Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89 (2004) 2548-2556
41. Gastaldelli A., Cusi K., Pettiti M., et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133 (2007) 496-506
42. Garg A. Adipose tissue dysfunction in obesity and lipodystrophy. Clin Cornerstone 8 Suppl 4 (2006) S7-S13
43. Dandona P., Aljada A., Chaudhuri A., et al. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111 (2005) 1448-1454
44. Knowler W.C., Barrett-Connor E., Fowler S.E., et al., for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
45. Orchard T.J., Temprosa M., Goldberg R., et al., for the Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial. Ann Intern Med 142 (2005) 611-619
46. Christensen R., Kristensen P.K., Bartels E.M., et al. Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet 370 (2007) 1706-1713
47. Després J.P., Golay A., Sjöström L., and for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134